SCHEMBL15068474

SCHEMBL15068474

C[C@@H]1CN(c2cc3ccccc3oc2=O)C[C@H](C)N1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
TYR P14679 1/20 0.43
DAO P14920 1/20 0.43
AKR1B1 P15121 1/20 0.43
POLB P06746 1/20 0.43
KDM4E B2RXH2 5/20 0.42
MAOB P27338 3/20 0.42
CA12 O43570 3/20 0.42
CA9 Q16790 3/20 0.42
CYP1A2 P05177 2/20 0.42
NT5E P21589 1/20 0.42
RAB9A P51151 4/20 0.41
ALDH1A1 P00352 5/20 0.41
MAOA P21397 2/20 0.41
LMNA P02545 3/20 0.40
MAPT P10636 2/20 0.40
NPC1 O15118 1/20 0.40
PKM P14618 1/20 0.40
CA1 P00915 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15066938 0.86 ALDH1A1 (0.43) HPGDSMN1; SMN2TYRDAOAKR1B1
SCHEMBL15068505 0.86 ALDH1A1 (0.43) HPGDSMN1; SMN2TYRDAOAKR1B1
SCHEMBL15068569 0.83 KDM4E (0.43) HPGDSMN1; SMN2TYRDAOAKR1B1
SCHEMBL722215 0.77 BACE1 (0.55) HPGDSMN1; SMN2TYRDAOAKR1B1
SCHEMBL15066296 0.76 BRD4 (0.43) HPGDSMN1; SMN2POLBKDM4EMAOB
SCHEMBL17144366 0.76 HSD17B10 (0.55) HPGDSMN1; SMN2TYRDAOAKR1B1
Hydrochloric Acid SCHEMBL15066499 0.75 BACE1 (0.54) HPGDSMN1; SMN2TYRDAOAKR1B1
SCHEMBL5867498 0.75 MAOA (0.56) HPGDSMN1; SMN2TYRDAOAKR1B1
Hydrochloric Acid SCHEMBL5501060 0.74 BACE1 (0.53) HPGDSMN1; SMN2TYRDAOAKR1B1
SCHEMBL9229823 0.72 POLB (0.40) HPGDSMN1; SMN2POLBMAOBCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE47689-E1 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2019-11-05 US disclosed
US-9617268-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2017-04-11 US disclosed
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY F. HOFFMANN-LA ROCHE AG (CH) 2015-04-30 US disclosed
EP-2797592-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC Therapeutics, Inc. (US) 2014-11-05 EP disclosed
WO-2013101974-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2013-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, RBM17, RBM22 HPGD 3080/4885SMN1; SMN2 1/4885TYR 3366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.